<DOC>
	<DOCNO>NCT01867762</DOCNO>
	<brief_summary>The purpose study assess effectiveness safety JNJ 49095397 participant symptomatic moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>An Effectiveness Safety Study Inhaled JNJ 49095397 ( RV568 ) Patients With Moderate Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled ( inactive substance compare medication test whether medication real effect clinical study ) , multicenter , parallel-group ( group participant treat time ) study . Approximately 200 participant randomly assign JNJ 49095397 placebo ratio 1:1 . The study consist 3 phase : screening ( 3 week ) , double-blind treatment ( 12 week ) , follow ( 4 week ) . Safety evaluation include assessment adverse event , vital sign , physical examination , electrocardiogram , clinical laboratory test monitor throughout study . The total duration study participant approximately 19 week .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Men woman nonchildbearing potential , Global Initiative Chronic Obstructive Lung Disease ( GOLD 2 3 ) , forced expiratory volume one second ( FEV1 ) great equal 40 less 80 percent predict , FEV1/ force vital capacity ( FVC ) ratio le 0.7 Clinical history chronic bronchitis . Either two chronic obstructive pulmonary disease ( COPD ) exacerbation past two year ability produce spontaneous sputum sample , treat longacting beta2 agonist ( LABA ) / longacting muscarinic antagonist ( LAMA ) , without inhaled corticosteroid least 12 week prior study entry Smoker exsmoker least 10 packyear history No COPD exacerbation require change COPD maintenance medication screen period Not experienced significant worsen COPD base clinical symptom investigation screen period Has another pulmonary disease ( eg , asthma ) active infection ( eg , tuberculosis ) Has experience lifethreatening COPD ( eg , require intensive care unit [ ICU ] admission , intubation , longterm noninvasive ventilation ) . Shortterm ( less five day ) , noninvasive ventilation hospitalization acute exacerbation COPD permit , provide noninvasive ventilation continue home Has right heart failure oxygen saturation le 90 percent rest room air screen require oxygen therapy daily basis chronic hypoxemia ( deficiency oxygen blood ) History significant disease medical illness within 12 month prior screen Positive serology human immunodeficiency virus ( HIV ) 1 HIV2 , hepatitis B virus , hepatitis C virus screen</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>JNJ 49095397</keyword>
	<keyword>RV568</keyword>
	<keyword>Forced expiratory volume one second</keyword>
	<keyword>FEV1</keyword>
</DOC>